News RevMed hails first-line data with pancreatic cancer drug Revolution Medicine's fast-growing pan-RAS inhibitor Rasonque has generated exciting results as a first-line treatment for pancreatic cancer.
News Macmillan lends support to UK prostate cancer data project Prostate Progress, a data-powered project to find better tests, treatments, and care for prostate cancer, is expanding via an alliance with Macmillan.
Oncology On looking to a future multiomics approach for CDx, with Jan... The pharmaphorum podcast caught up with Jane Li, VP and general manager for companion diagnostics at Thermo Fisher Scientific, following ESMO 2026.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
News GSK gets second cancer drug approval from Nuvalent buy The FDA has cleared GSK's ALK inhibitor Nelkarmi for a form of lung cancer, the second product from its $10.6bn acquisition of Nuvalent.
News Roche joins the oral SERD club as FDA clears Wilserdly Roche is the latest drugmaker to bring an oral SERD drug for breast cancer to the US market, after getting FDA approval for its Wilserdly product.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.